Summary by Moomoo AI
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VVOS, has reported a compliance issue in a Current Report on Form 8-K filed with the SEC. The report, dated May 17, 2024, with events reported as of May 16, 2024, details the company's ongoing struggle to meet the Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Despite previous capital raising efforts that led the company to believe it had regained compliance as of March 19, 2024, a new notice from Nasdaq on May 16, 2024, indicated that Vivos Therapeutics' stockholders' equity had fallen below the required threshold. As a result, Nasdaq has initiated delisting proceedings. The company has appealed this determination and is actively working...Show More